Detail akcie Tempus AI Rg-A online

Business Summary: Tempus AI, Inc. is a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare. The Company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics. Its product lines include genomics, data, and artificial intelligence applications (AI). Its genomics product line leverages its laboratories to provide next generation sequencing (NGS) diagnostics, polymerase chain reaction (PCR), profiling, molecular genotyping, and other anatomic and molecular pathology testing. The data generated in its lab or ingested into its platform is structured and de-identified, prior to commercialization. Its AI Applications is focused on developing and providing diagnostics that are algorithmic in nature, implementing new software as a medical device, and building and deploying clinical decision support tools.
Financial Summary: BRIEF: For the three months ended 31 March 2025, Tempus AI Inc revenues increased 75% to $255.7M. Net loss applicable to common stockholders decreased 27% to $68M. Revenues reflect Genomics increase of 89% to $193.8M, Data and services increase of 43% to $61.9M. Basic Earnings per Share excluding Extraordinary Items increased from -$0.56 to -$0.40.